Alethia Biotherapeutics Adds $4.7M in Financing
Alethia Biotherapeutics Inc., a company developing “therapeutic monoclonal antibodies,” has added $4.7 million in new financing. Investors include AgeChem Venture Fund, BDC Venture Capital, GO Capital, and Cellscript of Wisconsin. Alethia Biotherapeutics is based in Montreal.
2 November 2012•3 mins read
